ClinicalTrials.gg
CompletedNCT01646177UNCOVER-3Updated Jul 28, 2020Results posted

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

A Phase 3 interventional study of Placebo and 50 mg etanercept in Psoriasis, sponsored by Eli Lilly and Company. Completed at 101 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
Largest of 22
1,346 · median 156
Started
2012
with 2 others
Phase 3
11 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one has the largest enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presents with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis for at least 6 months prior to randomization
  • At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization
  • Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization
  • Candidate for phototherapy and/or systemic therapy
  • Men must agree to use a reliable method of or remain abstinent during the study
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion criteria

Exclusion Criteria:

  • Pustular, erythrodermic, and/or guttate forms of psoriasis
  • History of drug-induced psoriasis
  • Prior use of etanercept
  • flare of psoriasis during the 12 weeks prior to randomization
  • Concurrent or recent use of any biologic agent
  • Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens and ultraviolet A [PUVA], ultraviolet B [UVB]) within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study
  • Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
  • Serious disorder or illness other than plaque psoriasis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,346 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.

    Drug: Placebo

  • Active comparator
    50 mg etanercept

    Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2

    Drug: 50 mg etanercept

  • Experimental
    80 mg ixekizumab Dosing Regimen 2

    Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.

    Drug: 80 mg ixekizumab

  • Experimental
    80 mg ixekizumab Dosing Regimen 1

    Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.

    Drug: 80 mg ixekizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)

    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.

    Time frame: Week 12

  2. Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)

    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.

    Time frame: Week 12

  2. Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

    Time frame: Week 12

  3. Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

    Time frame: Week 12

  4. Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]

    The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Week 12

  5. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score

    The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  7. Percent of Body Surface Area (BSA) Involvement of Psoriasis

    Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Week 12

  8. Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score

    PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]

    The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.

    Time frame: Baseline, Week 12

  10. Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)

    The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.

    Time frame: Baseline, Week 12

  11. Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Patient's Global Assessment of Disease Severity

    The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

    Time frame: Baseline, Week 12

  13. Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement

    Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.

    Time frame: Week 12

  14. Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement

    Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.

    Time frame: Week 12

  15. Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement

    Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.

    Time frame: Week 12

  16. Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies

    The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population \* 100.

    Time frame: Week 12

07

Results

Posted Oct 21, 2016

Participant flow

Blinded Induction Dosing (Week 0-12)
Participant flow — Blinded Induction Dosing (Week 0-12)
MilestonePlacebo50 mg Etanercept (ETN)80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)PBO/IXE80Q4WETN/IXE80Q4WIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q4WPBO Follow-Up PeriodETN Follow-Up PeriodIXE80Q4W Follow-Up PeriodIXE80Q2W Follow-Up Period
Started19338238638500000000
Received at least one dose of study drug19338238238400000000
Completed18336936036300000000
Not completed1013262200000000
Withdrew: Adverse event249800000000
Withdrew: Protocol violation138700000000
Withdrew: Withdrawal by subject324400000000
Withdrew: Physician decision121200000000
Withdrew: Lack of efficacy002100000000
Withdrew: Lost to follow-up322000000000
Long-Term Extension Period (Week 12-264)
Participant flow — Long-Term Extension Period (Week 12-264)
MilestonePlacebo50 mg Etanercept (ETN)80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)PBO/IXE80Q4WETN/IXE80Q4WIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q4WPBO Follow-Up PeriodETN Follow-Up PeriodIXE80Q4W Follow-Up PeriodIXE80Q2W Follow-Up Period
Started00001833693603620000
Received at least one dose of study drug00001833693603620000
Completed00001352562442550000
Not completed0000481131161070000
Withdrew: Adverse event0000163443300000
Withdrew: Withdrawal by subject0000113029270000
Withdrew: Lost to follow-up000061723180000
Withdrew: Lack of efficacy000061410110000
Withdrew: Physician decision000035550000
Withdrew: Protocol violation000014050000
Withdrew: Sponsor decision000032220000
Withdrew: Death000013130000
Withdrew: Clinical relapse000011140000
Withdrew: Parent/caregiver decision000000010000
Withdrew: Missing disposition form000003210000
Follow-Up Period (Minimum of 12 Weeks)
Participant flow — Follow-Up Period (Minimum of 12 Weeks)
MilestonePlacebo50 mg Etanercept (ETN)80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)PBO/IXE80Q4WETN/IXE80Q4WIXE80Q4W/IXE80Q4WIXE80Q2W/IXE80Q4WPBO Follow-Up PeriodETN Follow-Up PeriodIXE80Q4W Follow-Up PeriodIXE80Q2W Follow-Up Period
Started00000000157309305313
Received at least one dose of study drug00000000157309305313
Completed00000000126233225230
Not completed0000000031768083
Withdrew: Adverse event0000000013283430
Withdrew: Withdrawal by subject000000007211919
Withdrew: Lost to follow-up000000004899
Withdrew: Lack of efficacy000000004989
Withdrew: Protocol violation000000001647
Withdrew: Physician decision000000001223
Withdrew: Clinical relapse000000000113
Withdrew: Sponsor decision000000000111
Withdrew: Death000000001011
Withdrew: Entry criteria not met000000000011

Outcome measures

PrimaryNumber of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)

The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)13159291310
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
PrimaryNumber of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)14204325336
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)

The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)033139155
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving ≥90% (PASI 90) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)698252262
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving 100% (PASI 100) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: PASI)028135145
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]

The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Participants indicate their overall severity of itching from Psoriasis by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]33200250264
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score-1.7 ± 0.32-8.0 ± 0.23-9.6 ± 0.23-10.2 ± 0.23
Statistical analysis
  • Placebo vs 50 mg Etanercept · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI) Score

The NAPSI is a numeric, reproducible, objective tool used to evaluate the severity of fingernail bed psoriasis and fingernail matrix psoriasis by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed psoriasis: 0 (none) to 4 (psoriasis in 4 quadrants of the nail) and fingernail matrix psoriasis (0 to 4) depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed and fingernail matrix psoriasis in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, and the sum of all the fingernails is the total NAPSI score (range, 0 to 80). LS Means in NAPSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score1.6362 ± 1.0991-6.4015 ± 0.7716-9.9793 ± 0.7838-10.4145 ± 0.7820
Statistical analysis
  • Placebo vs 50 mg Etanercept · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Mixed Models Analysis · p = <0.001
SecondaryPercent of Body Surface Area (BSA) Involvement of Psoriasis

Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb). LS Means in BSA were calculated using MMRM with baseline BSA as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Week 12
Reported as:
Least squares mean · Percent
Percent of Body Surface Area (BSA) Involvement of Psoriasis
PercentPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Percent of Body Surface Area (BSA) Involvement of Psoriasis-0.7 ± 1.03-16.4 ± 0.73-23.2 ± 0.73-23.2 ± 0.73
Statistical analysis
  • Placebo vs 50 mg Etanercept · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Psoriasis Scalp Severity Index (PSSI) Score

PSSI is a composite score ranging from 0 (best) to 72 (worst), derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of scalp area involved. LS Means in PSSI score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score-5.0 ± 0.53-15.9 ± 0.38-18.2 ± 0.38-18.8 ± 0.38
Statistical analysis
  • Placebo vs 50 mg Etanercept · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]

The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS Means in total QIDS-SR16 score were calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]-0.3 ± 0.20-0.5 ± 0.14-0.9 ± 0.14-1.3 ± 0.14
Statistical analysis
  • Placebo vs 50 mg Etanercept · ANCOVA · p = 0.473
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = 0.015
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = <0.001
SecondaryChange From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)

The WPAI-PSO is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days. It has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as: each score \* 100 and ranged from 0 to 100. Higher scores indicate greater impairment in productivity. LS Means in each WPAI-PSO score were calculated using the ANCOVA model with treatment, pooled center and baseline WPAI-PSO score.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Absenteeism Score0.0 ± 0.82-2.8 ± 0.62-2.0 ± 0.60-2.5 ± 0.61
Activity Impairment Score-2.5 ± 1.30-21.1 ± 0.91-23.3 ± 0.92-24.5 ± 0.92
Presenteeism Score-0.8 ± 1.37-16.4 ± 1.04-16.0 ± 1.01-18.1 ± 1.04
Work Productively Loss Score0.6 ± 1.59-17.4 ± 1.20-16.7 ± 1.16-19.3 ± 1.19
Statistical analysis
  • Placebo vs 50 mg Etanercept · ANCOVA · p = 0.006
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = 0.045
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = 0.012
  • Placebo vs 50 mg Etanercept · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = <0.001
  • Placebo vs 50 mg Etanercept · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = <0.001
  • Placebo vs 50 mg Etanercept · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = <0.001
SecondaryChange From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS Means in SF-36 score were calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey, Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
PCS-0.1993 ± 0.50773.1176 ± 0.35684.1143 ± 0.35873.9620 ± 0.3604
MCS1.1305 ± 0.57682.6486 ± 0.40473.7961 ± 0.40744.2772 ± 0.4093
Statistical analysis
  • Placebo vs 50 mg Etanercept · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = <0.001
  • Placebo vs 50 mg Etanercept · ANCOVA · p = 0.031
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · ANCOVA · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · ANCOVA · p = <0.001
SecondaryChange From Baseline in Patient's Global Assessment of Disease Severity

The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Means in Patient's Global Assessment of Disease Severity score were calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Patient's Global Assessment of Disease Severity
Units on a ScalePlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Change From Baseline in Patient's Global Assessment of Disease Severity-0.5 ± 0.08-2.3 ± 0.06-3.1 ± 0.06-3.1 ± 0.06
Statistical analysis
  • Placebo vs 50 mg Etanercept · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Mixed Models Analysis · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Mixed Models Analysis · p = <0.001
SecondaryNumber of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement

Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 50 were defined as having an improvement of at least 50% in the PPASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving Palmoplantar PASI of ≥50% (PPASI 50) Improvement26777578
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement

Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 75 were defined as having an improvement of at least 75% in the PPASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving Palmoplantar PASI of ≥75% (PPASI 75) Improvement19636972
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement

Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. Participants achieving PPASI 100 were defined as having an improvement of 100% in the PPASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants Achieving Palmoplantar PASI of 100% (PPASI 100) Improvement15575461
Statistical analysis
  • Placebo vs 50 mg Etanercept · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 2 (Q4W) · Cochran-Mantel-Haenszel · p = <0.001
  • Placebo vs 80 mg Ixekizumab Dosing Regimen 1 (Q2W) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies

The percentage of participants with treatment-emergent positive anti-ixekizumab antibodies at any time post-baseline were summarized by treatment group. Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies were calculated as: number of participants with an evaluable baseline sample and ≥1 evaluable post-baseline sample/number of participants in the analysis population \* 100.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies
ParticipantsPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)
Number of Participants With Treatment-Emergent Anti-Ixekizumab Antibodies285223

Adverse events

Collected over Up to 288 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/193 (2.6%)40/193 (20.7%)
50 mg Etanercept—8/382 (2.1%)90/382 (23.6%)
80 mg Ixekizumab Dosing Regimen 2 (Q4W)—6/382 (1.6%)115/382 (30.1%)
80 mg Ixekizumab Dosing Regimen 1 (Q2W)—9/384 (2.3%)123/384 (32%)
PBO/IXE80Q4W Long-Term Extension—45/183 (24.6%)117/183 (63.9%)
ETN/IXE80Q4W Long-Term Extension—71/369 (19.2%)240/369 (65%)
IXE80Q4W/IXE80Q4W Long-Term Extension—82/360 (22.8%)236/360 (65.6%)
IXE80Q2W/IXE80Q4W Long-Term Extension—55/362 (15.2%)249/362 (68.8%)
PBO Follow-Up Period—5/157 (3.2%)9/157 (5.7%)
ETN Follow-Up Period—5/309 (1.6%)23/309 (7.4%)
IXE80Q4W Follow-Up—2/305 (0.7%)14/305 (4.6%)
IXE80Q2W Follow-Up—6/313 (1.9%)15/313 (4.8%)
Most frequent serious events
Showing 10 of 308
Most frequent serious events
EventPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)PBO/IXE80Q4W Long-Term ExtensionETN/IXE80Q4W Long-Term ExtensionIXE80Q4W/IXE80Q4W Long-Term ExtensionIXE80Q2W/IXE80Q4W Long-Term ExtensionPBO Follow-Up PeriodETN Follow-Up PeriodIXE80Q4W Follow-UpIXE80Q2W Follow-Up
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/560/1130/1280/1300/541/1092/1190/1210/491/920/1000/104
CellulitisInfections and infestations1/1930/3820/3820/3843/1834/3693/3601/3620/1570/3090/3050/313
DiverticulitisInfections and infestations0/1930/3820/3820/3843/1830/3690/3601/3620/1570/3090/3050/313
CholelithiasisHepatobiliary disorders0/1930/3820/3821/3840/1832/3694/3604/3620/1570/3090/3051/313
OsteoarthritisMusculoskeletal and connective tissue disorders0/1931/3820/3820/3841/1834/3694/3601/3620/1570/3090/3050/313
Atrial fibrillationCardiac disorders0/1930/3820/3820/3842/1833/3690/3600/3620/1570/3090/3050/313
Myocardial infarctionCardiac disorders0/1930/3820/3820/3842/1832/3693/3602/3620/1570/3090/3050/313
CholecystitisHepatobiliary disorders0/1930/3820/3820/3842/1830/3690/3601/3620/1570/3090/3051/313
FallInjury, poisoning and procedural complications1/1931/3820/3821/3842/1832/3692/3601/3620/1570/3090/3051/313
Back painMusculoskeletal and connective tissue disorders0/1930/3820/3820/3842/1830/3691/3600/3620/1570/3090/3050/313
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlacebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)PBO/IXE80Q4W Long-Term ExtensionETN/IXE80Q4W Long-Term ExtensionIXE80Q4W/IXE80Q4W Long-Term ExtensionIXE80Q2W/IXE80Q4W Long-Term ExtensionPBO Follow-Up PeriodETN Follow-Up PeriodIXE80Q4W Follow-UpIXE80Q2W Follow-Up
NasopharyngitisInfections and infestations11/19319/38229/38226/38455/183104/369107/360112/3624/1574/3095/3052/313
Upper respiratory tract infectionInfections and infestations5/1938/3828/3828/38421/18333/36948/36042/3620/1571/3091/3052/313
ArthralgiaMusculoskeletal and connective tissue disorders4/1937/3829/38213/38417/18320/36929/36041/3620/1571/3091/3051/313
Injection site reactionGeneral disorders3/19342/38243/38237/38418/18324/36934/36024/3620/1570/3090/3050/313
HypertensionVascular disorders2/1939/3823/3825/38420/18330/36930/36026/3621/1572/3090/3050/313
BronchitisInfections and infestations0/1934/3826/3821/38417/18320/36924/36036/3620/1570/3091/3053/313
SinusitisInfections and infestations2/1931/3821/3824/38416/18310/36928/36027/3620/1571/3091/3051/313
Back painMusculoskeletal and connective tissue disorders2/1932/3828/3827/38416/18328/36923/36030/3621/1571/3090/3050/313
HeadacheNervous system disorders5/19311/38216/38216/3849/18330/36923/36027/3620/1572/3091/3052/313
DiarrhoeaGastrointestinal disorders2/1936/3823/38211/38410/18327/36914/36025/3620/1570/3090/3050/313

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Placebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)Total
<=18 years00000
Between 18 and 65 years1803493583511238
>=65 years13332834108
Sex: Female, Male
Sex: Female, Male(Participants)Placebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)Total
Female56113128131428
Male137269258254918
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)Total
Hispanic or Latino25525057184
Not Hispanic or Latino133263269259924
Unknown or Not Reported35676769238
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)Total
American Indian or Alaska Native144110
Asian711111241
Native Hawaiian or Other Pacific Islander01146
Black or African American8109532
White1763513603611248
More than one race15129
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Placebo50 mg Etanercept80 mg Ixekizumab Dosing Regimen 2 (Q4W)80 mg Ixekizumab Dosing Regimen 1 (Q2W)Total
Argentina276621
Chile1121222276
Mexico12115
Bulgaria912141348
Germany45879090312
Hungary18313133113
Poland510111339
Russia1122202477
Canada22444442152
United States69146147141503
08

Study locations

101 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anaheim, California 92801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bakersfield, California 93309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bell Gardens, California 90201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beverly Hills, California 90212, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Irvine, California 92697, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oceanside, California 92056, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92123, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Monica, California 90404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aurora, Colorado 80045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Haven, Connecticut 06511, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edgewater, Florida 32132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ocala, Florida 34471, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ormond Beach, Florida 32174, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arlington Heights, Illinois 60005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Skokie, Illinois 60077, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46256, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Des Moines, Iowa 50265, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40217, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Owensboro, Kentucky 42303, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boston, Massachusetts 02111, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ann Arbor, Michigan 48109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Henderson, Nevada 89074, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newington, New Hampshire 03801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    East Windsor, New Jersey 08520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albuquerque, New Mexico 87106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10075, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stony Brook, New York 11790, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    High Point, North Carolina 27262, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winston-Salem, North Carolina 27157, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97223, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hazleton, Pennsylvania 18201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anderson, South Carolina 29621, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75246, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Jordan, Utah 84088, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1055AA0, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autónoma De Buenosaire, C1199ABD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plovdiv, 4000, Bulgaria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sofia, 1632, Bulgaria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Varna, 9010, Bulgaria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T3A 2N1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, British Columbia V5Z-3Y1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halifax, Nova Scotia B3H0A2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brampton, Ontario L6R 0W3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottawa, Ontario K2G 6E2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond Hill, Ontario L4B 1A5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waterloo, Ontario N2J 1C4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Windsor, Ontario N8W5L7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Drummondville, Quebec J2B 5L4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H2K4L5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santiago, 8420383, Chile
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augsburg, 86179, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13125, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bonn, 53111, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01069, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Erfurt, 99084, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ergolding, 84038, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt, 60596, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freiburg, 79100, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freising, 85354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Friedrichshafen, 88045, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gera, 07548, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20253, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hanau, 63450, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kiel, 24148, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04103, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mahlow, 15831, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mannheim, 68167, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mönchengladbach, 41236, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Münster, 48159, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Northeim, 37154, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Schwerin, 19055, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Würzburg, 97080, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1036, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Debrecen, 4032, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kecskemet, 6000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mako, 6900, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miskolc, 3529, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oroshaza, 5900, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pecs, 7632, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szeged, H-6720, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szolnok, H-5000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szombathely, 9700, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Veszprem, 8200, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64460, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-017, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krakow, 30-510, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-201, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krasnodar, 350020, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 127473, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 194356, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sankt-Peterburg, 195112, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Smolensk, 214019, Russian Federation

Showing the first 100 of 101 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatol Ther (Heidelb). 2022 Apr;12(4):911-920. doi: 10.1007/s13555-022-00704-2. Epub 2022 Mar 13. PubMed 35279805 ↗
  • Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, Gallo G, Paul C. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021 Aug;85(2):360-368. doi: 10.1016/j.jaad.2020.11.022. Epub 2020 Nov 28. PubMed 33253833 ↗
  • Rich P, Goldblum O, Disch D, Lin CY, Merola JF, Elewski B. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis. J Drugs Dermatol. 2020 Aug 1;19(8):741-746. doi: 10.36849/JDD.2020.5116. PubMed 32845588 ↗
  • Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, Berggren L, Henneges C, Luger T. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. Dermatol Ther (Heidelb). 2018 Dec;8(4):621-637. doi: 10.1007/s13555-018-0267-9. Epub 2018 Nov 21. PubMed 30465321 ↗
  • Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, Muram TM, Blauvelt A. Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. J Invest Dermatol. 2018 Oct;138(10):2168-2173. doi: 10.1016/j.jid.2018.04.019. Epub 2018 May 8. PubMed 29751001 ↗
  • Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9. Erratum In: Am J Clin Dermatol. 2018 Jun;19(3):457. doi: 10.1007/s40257-018-0353-x. PubMed 28074446 ↗
  • van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2. PubMed 27910156 ↗
  • Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. PubMed 27299809 ↗
  • Armstrong AW, Lynde CW, McBride SR, Stahle M, Edson-Heredia E, Zhu B, Amato D, Nikai E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 Jun 1;152(6):661-9. doi: 10.1001/jamadermatol.2016.0269. PubMed 26953848 ↗
  • Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. PubMed 26072109 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in May 2014, 21 months.

Results were first posted in Oct 2016, 2 years 4 months after primary completion. A results delay was requested in Sep 2014.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2012
First posted
Jul 20, 2012
StartActual
Jul 28, 2012
Primary completionActual
May 22, 2014
CompletionActual
Jul 22, 2019
Results delay requested
Sep 29, 2014
Results first posted
Oct 21, 2016
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01646177
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Jul 28, 2012
Primary completion
May 22, 2014
Completion
Jul 22, 2019
Results posted
Oct 21, 2016
Last update
Jul 28, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion